Wcn23-0069 efficacy and safety of reduced-dose oral methylprednisolone in iga nephropathy: the testing trial

The TESTING study recently reported that corticosteroids reduce the risk of major kidney events and kidney failure in individuals with IgA nephropathy (IgAN) at high risk of disease progression compared to supportive care alone, but that these benefits come with an increased risk of serious adverse events (SAE) primarily with full-dose therapy. The risk-benefit balance of the reduced-dose regimen is therefore important to define. Here we report the efficacy and safety of methylprednisolone in the reduced-dose cohort of the TESTING study.